Provided herein is the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. Provided herein are methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

An electrochemically active device for collecting and retaining a biological sample with a bioanalyte, the device provided with at least a two-electrode member and an albumin-binding and an electrochemically active receptor in chemical contact with the two-electrode members and the biological sample. The present invention also provides a point-of-care biosensor with the device of the present invention and a method for measuring a bioanalyte in a biological sample. The device, point-of-care biosensor and the method of the present invention facilitate accurate measurements concentrations of urine albumin, human serum albumin (HSA), glycated albumin (GA) and methemalbumin (MHA) by determining redox current values in reduced volumes of biological samples.

The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.

An object of the present invention is to provide a method for predicting prognosis for a cancer patient. The present invention provides a method for predicting prognosis for a cancer patient, wherein at least one index selected from the group consisting of an index of nutritional state, an index of sugar metabolism state, and an index of inflammatory state in the cancer patient is used as an index of prognosis. The index of nutritional state is preferably a concentration of albumin in the blood, the index of sugar metabolism state is preferably a concentration of glucose in the blood, and the index of inflammatory state is preferably a concentration of CRP in the blood.

There is provided a method for measuring an antigen, comprising: providing a solution containing an antigen; providing a first antibody that specifically recognizes the antigen and is bound to a magnetic carrier; providing a second antibody that specifically recognizes the antigen and is modified with an oxidase; providing (a substrate liquid including) a substrate which reacts with the oxidase; allowing the first antibody to recognize the antigen; allowing the second antibody to recognize the antigen; using a magnetic field to capture an antigen-antibody complex of the antigen recognized by the first antibody and the second antibody in the magnetic field; washing the antigen-antibody complex while it is captured in the magnetic field; reacting the substrate with the antigen-antibody complex to produce hydrogen peroxide; and measuring the hydrogen peroxide.

A test strip for urinalysis is provided, the test strip including a reagent pad for detecting a concentration of a selected analyte, the reagent pad attached to the test strip and comprising a substrate and an analyte detection system retained thereon, the analyte detection system including a plurality of components necessary for detection of the selected analyte, wherein at least one of the plurality of components is a variable component, the variable component immobilized on the substrate at a plurality of amounts on the reagent pad.

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

Biochemical test methods for protein quantification can include application of foam-suppressing and/or foam-destroying substances to avoid readout problems and ensure the accuracy of measurement results. One such method for determining the amount of one or more proteins in a solution includes providing at least a first solution that is known to contain or suspected of containing one or more protein(s), adding at least one foam-suppressing and/or foam-destroying substance to the first solution, resulting in a second solution, and determining the amount of the one or more protein(s) in the second solution.

The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Systems and methods for tracking healing progress of multiple adjacent wounds are provided. In one embodiment, a system may include a processor configured to receive a first image of a plurality of adjacent wounds near a form of colorized surface having colored reference elements, determine colors of the plurality of wounds, correct for local illumination conditions, receive a second image of the plurality of wounds near the form of colorized surface, to determine second colors of the plurality of wounds in the second image, match each of the plurality of wounds in the second image to a wound of the plurality of wounds in the first image, and determine an indicator of the healing progress for each of the plurality of wounds based on changes between the first image and the second image.